David M. Spencer - Net Worth and Insider Trading

David M. Spencer Net Worth

The estimated net worth of David M. Spencer is at least $672 dollars as of 2024-06-01. David M. Spencer is the Chief Technology Officer of Bellicum Pharmaceuticals Inc and owns about 8,994 shares of Bellicum Pharmaceuticals Inc (BLCM) stock worth over $672. Details can be seen in David M. Spencer's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that David M. Spencer has not made any transactions after 2018-09-04 and currently still holds the listed stock(s).

Transaction Summary of David M. Spencer

To

David M. Spencer Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, David M. Spencer owns 1 companies in total, including Bellicum Pharmaceuticals Inc (BLCM) .

Click here to see the complete history of David M. Spencer’s form 4 insider trades.

Insider Ownership Summary of David M. Spencer

Ticker Comapny Transaction Date Type of Owner
BLCM Bellicum Pharmaceuticals Inc 2018-09-04 Chief Scientific Officer

David M. Spencer Latest Holdings Summary

David M. Spencer currently owns a total of 1 stock. David M. Spencer owns 8,994 shares of Bellicum Pharmaceuticals Inc (BLCM) as of September 4, 2018, with a value of $672.

Latest Holdings of David M. Spencer

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
BLCM Bellicum Pharmaceuticals Inc 2018-09-04 8,994 0.07 672

Holding Weightings of David M. Spencer


David M. Spencer Form 4 Trading Tracker

According to the SEC Form 4 filings, David M. Spencer has made a total of 0 transactions in Bellicum Pharmaceuticals Inc (BLCM) over the past 5 years. The most-recent trade in Bellicum Pharmaceuticals Inc is the sale of 1,000 shares on September 4, 2018, which brought David M. Spencer around $70,400.

Insider Trading History of David M. Spencer

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

David M. Spencer Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

David M. Spencer Ownership Network

Ownership Network List of David M. Spencer

No Data

Ownership Network Relation of David M. Spencer

Insider Network Chart

David M. Spencer Owned Company Details

What does Bellicum Pharmaceuticals Inc do?

Who are the key executives at Bellicum Pharmaceuticals Inc?

David M. Spencer is the Chief Scientific Officer of Bellicum Pharmaceuticals Inc. Other key executives at Bellicum Pharmaceuticals Inc include Chief Development Officer Charity Scripture , Principal Accounting Officer Charles S. Grass , and director & President and CEO Richard A. Fair .

Bellicum Pharmaceuticals Inc (BLCM) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Bellicum Pharmaceuticals Inc (BLCM) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Bellicum Pharmaceuticals Inc (BLCM) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Bellicum Pharmaceuticals Inc (BLCM)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Bellicum Pharmaceuticals Inc Insider Transactions

No Available Data

David M. Spencer Mailing Address

Above is the net worth, insider trading, and ownership report for David M. Spencer. You might contact David M. Spencer via mailing address: C/o Bellicum Pharmaceuticals, Inc., 2130 W. Holcombe Blvd., Ste. 800, Houston Tx 77030.

Discussions on David M. Spencer

No discussions yet.